A detailed history of Nantahala Capital Management, LLC transactions in Neuro Pace Inc stock. As of the latest transaction made, Nantahala Capital Management, LLC holds 778,260 shares of NPCE stock, worth $5.88 Million. This represents 0.66% of its overall portfolio holdings.

Number of Shares
778,260
Previous 1,173,677 33.69%
Holding current value
$5.88 Million
Previous $12.1 Million 15.1%
% of portfolio
0.66%
Previous 0.82%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$9.78 - $17.5 $3.87 Million - $6.92 Million
-395,417 Reduced 33.69%
778,260 $10.3 Million
Q4 2023

Feb 14, 2024

SELL
$5.9 - $10.31 $272,804 - $476,713
-46,238 Reduced 3.79%
1,173,677 $12.1 Million
Q3 2023

Nov 14, 2023

BUY
$4.0 - $9.73 $3.18 Million - $7.74 Million
795,065 Added 187.14%
1,219,915 $11.9 Million
Q2 2023

Aug 14, 2023

SELL
$3.98 - $5.12 $4,278 - $5,504
-1,075 Reduced 0.25%
424,850 $1.91 Million
Q1 2023

May 15, 2023

SELL
$1.44 - $5.34 $11,026 - $40,888
-7,657 Reduced 1.77%
425,925 $1.98 Million
Q4 2022

Feb 14, 2023

SELL
$1.29 - $2.98 $12,796 - $29,561
-9,920 Reduced 2.24%
433,582 $646,000
Q3 2022

Nov 10, 2022

SELL
$3.1 - $5.98 $108,301 - $208,917
-34,936 Reduced 7.3%
443,502 $1.66 Million
Q2 2022

Aug 15, 2022

SELL
$4.95 - $8.7 $33,981 - $59,725
-6,865 Reduced 1.41%
478,438 $2.37 Million
Q1 2022

May 13, 2022

BUY
$7.06 - $11.57 $1.27 Million - $2.08 Million
179,397 Added 58.64%
485,303 $3.98 Million
Q4 2021

Feb 14, 2022

BUY
$8.63 - $17.36 $1.42 Million - $2.85 Million
164,265 Added 115.97%
305,906 $3.08 Million
Q3 2021

Nov 15, 2021

SELL
$15.85 - $25.07 $91,343 - $144,478
-5,763 Reduced 3.91%
141,641 $2.25 Million
Q2 2021

Aug 16, 2021

BUY
$19.03 - $26.5 $2.81 Million - $3.91 Million
147,404 New
147,404 $3.51 Million

Others Institutions Holding NPCE

About NeuroPace Inc


  • Ticker NPCE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 24,846,900
  • Market Cap $188M
  • Description
  • NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and ena...
More about NPCE
Track This Portfolio

Track Nantahala Capital Management, LLC Portfolio

Follow Nantahala Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nantahala Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nantahala Capital Management, LLC with notifications on news.